 |
bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13) |
|---|---|
| Trade Name | |
| Orphan Indication | Idiopathic pulmonary fibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2011-09-14 00:00:00 |
| Sponsor | Sanofi-Aventis US, Inc.;200 Crossing Blvd;Bridgewater, New Jersey, 08807 |
